Efsubaglutide alfa added to metformin improves glycaemia with β-cell functional responses in type 2 diabetes: a randomised, double-blind, placebo-controlled, two-stage adaptive phase 2b/3 trial (SUPER 2).
Weiping Jia, Fei Gao, Jingyi Lu, Zhifeng Cheng, Xiaolin Dong, Xiaoxia Shi, Xiuhai Su, Liping Li, Wei Zhang, Yihua Wang, Jianhua Ma, Shu Li, Haifang Wang, Lin Cheng, Li Mao, Chengyan Jiang, Qingju Li, Xing Li, Xin Zheng, Ming Liu, Jiao Sun, Hui Peng, Huanfeng Pan, Hongwei Ling, Chengxia Jiang, Junhua Song, Xinhuan Zhang, Lili Zhang, Yang Liu, Tianshu Zeng, Yongcai Zhao, Yulong Xu, Yiming Li, Yuqian Bao, Jian Zhou, Qinghua Wang
Nat Commun 10.1038/s41467-026-72574-7
摘要
摘要
Efsubaglutide alfa, a long-acting humanised GLP-1 receptor agonist, was evaluated as add-on therapy to metformin in adults with type 2 diabetes. In an operationally seamless adaptive phase 2b/3, randomised, double-blind, placebo-controlled trial, phase 2b randomised participants 1:1:1 to Efsubaglutide 1 mg, 3 mg, or placebo for 12 weeks; based on phase 2b efficacy and safety, an independent committee selected 3 mg as the recommended phase 3 dose. Phase 3 randomised new participants 1:1 to Efsubaglutide 3 mg or placebo for 24-week double-blind treatment, followed by a 28-week open-label extension. At week 12 in phase 2b, HbA1c decreased by 1.10% with 1 mg and 1.43% with 3 mg (both p < 0.0001). At week 24 in phase 3, HbA1c decreased by 1.80% with Efsubaglutide 3 mg versus 0.74% with placebo (estimated treatment difference, -1.06%; p < 0.001). Adverse events were predominantly mild to moderate gastrointestinal events. Trial registration: ClinicalTrials.gov NCT04998032.
KM 提取结果
0 个 Figure · 0 个 KM 面板